Preclinical/Co-Clinical Section
临床前/临床联合部分
基本信息
- 批准号:10251355
- 负责人:
- 金额:$ 15.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAnimal ModelBenchmarkingBiologyBiomedical ResearchCLIA certifiedClientClinicalClinical DataClinical TrialsCollaborationsCollectionCommunitiesDataDisease modelDrug KineticsEnsureFacultyFee-for-Service PlansFelis catusFutureGeneticGenomic medicineGoalsGrantHealthHospitalsHumanHuman GeneticsIndividualIndustryIndustry CollaborationInfrastructureKnowledgeLaboratoriesLeadMedical centerModalityModelingMouse StrainsMusPatientsPharmacologyPhenotypePlug-inPositioning AttributePreclinical TestingProductionRare DiseasesRecommendationResearchResearch PersonnelResourcesRoleSamplingSeriesServicesTestingThe Jackson LaboratoryTherapeuticToxicologyTranslationsTreatment EfficacyValidationWorkbaseclinical applicationclinical phenotypeclinical practicedata exchangedrug testingexperiencegenomic datahuman diseasein vivomodel developmentoperationpre-clinicalprecision geneticsrepositorysomatic cell gene editingtool
项目摘要
PROJECT SUMMARY PRECLINICAL/CO-CLINICAL CORE
The Jackson Laboratory (JAX) and The Jackson Laboratory Center for Precision Genetics (JCPG) occupy a
unique niche within the global biomedical research community. Although we do not see patients, many of
these individuals have benefited from our stewardship of the thousands of different mouse strains that JAX
provides for use in human disease research. And it is not just our mice; our faculty researchers, with deep
expertise in genetics and mammalian biology, collaborate directly with investigators at hospitals, medical
centers and an array of other clinically oriented partners worldwide. Thus, the JCPG will operate using a “hub
and spokes” concept where the JCPG forms part of a mammalian disease model “hub” that integrates a variety
of JAX resources to establish an array of collaborative “spokes” with a variety of partners to co-produce precise
preclinical disease models. The Preclinical/Co-clinical core of the JCPG will work with expert clinical, patient,
research and industry collaborators to facilitate optimal creation and application of existing and nominated
projects. Together with the JCPG Coordination Core, the Preclinical/Co-clinical Core and the Steering
Committee will apply a series of benchmark standards to work toward the eventual goal of translation into
clinical practice. Ultimately, we will further extend our impact by providing a more advanced Fee for Service
approach to broaden community access to JAX resources. To meet current goals of the JCPG and to refine
and expand its future operation, the Preclinical/Co-clinical Core will: 1) Solicit, evaluate and prioritize new
preclinical/co-clinical project requests and provide recommendations to the Steering Committee for adoption by
the JCPG. 2) Advance new models through the production-like pipelines, with characterization and drug
testing so they can more tangibly inform future clinical applications. 3) Continue to develop and expand
existing JAX infrastructure to facilitate access to clinical data and samples, supporting data exchange between
mouse information and patient data.
项目摘要临床前/联合临床核心
杰克逊实验室(JAX)和杰克逊精密遗传学实验室中心(JCPG)占据了
在全球生物医学研究界独一无二的利基市场。虽然我们看不到病人,但很多人
这些人受益于我们对JAX病毒数以千计的不同小鼠品系的管理
可用于人类疾病研究。这不仅仅是我们的老鼠;我们的教职员工研究人员,
遗传学和哺乳动物生物学方面的专业知识,直接与医院、医疗机构的研究人员合作
中心和世界各地的一系列其他面向临床的合作伙伴。因此,中日联合联络小组将利用一个“枢纽”运作。
JCPG形成了哺乳动物疾病模型的一部分,该模型集成了各种
与各种合作伙伴建立一系列协作的“辐条”,共同制作PRECIST
临床前疾病模型。JCPG的临床前/联合临床核心将与专家临床、患者、
研究和行业合作伙伴,促进现有和提名的最佳创作和应用
项目。与JCPG协调核心、临床前/联合临床核心和指导
委员会将应用一系列基准标准来努力实现翻译成
临床实践。最终,我们将通过提供更高级的服务费用来进一步扩大我们的影响
扩大社区获取JAX资源的途径。以达到中日联合联络小组目前的目标并加以完善
并扩展其未来的业务,临床前/联合临床核心将:1)征集、评估和确定新的
临床前/联合临床项目申请,并向指导委员会提出建议,供#年通过
日中关系。2)通过类似生产的流水线推出新型号,包括表征和药品
测试,以便它们可以更切实地为未来的临床应用提供信息。3)继续发展壮大
现有的JAX基础设施可促进临床数据和样本的访问,支持
鼠标信息和患者数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cathleen M Lutz其他文献
Cathleen M Lutz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cathleen M Lutz', 18)}}的其他基金
Project 4: Therapeutic Gene Editing for Rett Syndrome
项目 4:雷特综合征的治疗性基因编辑
- 批准号:
10668770 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Interrogation of Neurological Pathologies Associated with Mutations in Kif1a
与 Kif1a 突变相关的神经病理学研究
- 批准号:
10728701 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
The Mutant Mouse Resource and Research Center at The Jackson Laboratory
杰克逊实验室突变小鼠资源和研究中心
- 批准号:
10400428 - 财政年份:2021
- 资助金额:
$ 15.12万 - 项目类别:
The Jackson Laboratory Center for Precision Genetics
杰克逊精密遗传学实验室中心
- 批准号:
10469581 - 财政年份:2020
- 资助金额:
$ 15.12万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 15.12万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Standard Grant